CSPC Innovation Pharmaceutical (300765.SZ) subsidiary receives US$15 million milestone payment under exclusive licensing agreement signed with Corbus.
CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlled subsidiary, CSPC Group Juishi Biopharmaceutical Co., Ltd. ("Juishi Biopharmaceutical"), received a US$15 million milestone payment from Corbus Pharmaceuticals, Inc. ("Corbus") on November 18, 2026. Prior to this, Juishi Biopharmaceutical had cumulatively received an aggregate of US$17.5 million in upfront and milestone payments from Corbus under the exclusive licensing agreement (excluding this payment). This payment is expected to have a positive impact on the company's performance and financial condition.
CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlled subsidiary CSPC PHARMA Jushi Biopharmaceutical Co., Ltd. ("Jushi Biopharmaceutical") received a US$15 million milestone payment from Corbus Pharmaceuticals, Inc. ("Corbus") on November 18, 2026. Prior to this, Jushi Biopharmaceutical had cumulatively received an upfront payment and milestone payments totaling US$17.5 million from Corbus under the exclusive licensing agreement (excluding this payment). This payment is expected to have a positive impact on the company's performance and financial condition.
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






